DK2509619T3 - Behandlingsfremgangsmåder ved hjælp af stamcellemobilisatorer og immunsuppressive midler - Google Patents

Behandlingsfremgangsmåder ved hjælp af stamcellemobilisatorer og immunsuppressive midler Download PDF

Info

Publication number
DK2509619T3
DK2509619T3 DK10836746.7T DK10836746T DK2509619T3 DK 2509619 T3 DK2509619 T3 DK 2509619T3 DK 10836746 T DK10836746 T DK 10836746T DK 2509619 T3 DK2509619 T3 DK 2509619T3
Authority
DK
Denmark
Prior art keywords
stem cell
treatment methods
immunosuppressive agents
cell mobilizers
mobilizers
Prior art date
Application number
DK10836746.7T
Other languages
English (en)
Inventor
Zhaoli Sun
George Melville Williams
Original Assignee
Medregen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medregen Llc filed Critical Medregen Llc
Application granted granted Critical
Publication of DK2509619T3 publication Critical patent/DK2509619T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10836746.7T 2009-12-11 2010-12-10 Behandlingsfremgangsmåder ved hjælp af stamcellemobilisatorer og immunsuppressive midler DK2509619T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28560209P 2009-12-11 2009-12-11
US31618010P 2010-03-22 2010-03-22
PCT/US2010/059877 WO2011072216A2 (en) 2009-12-11 2010-12-10 Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

Publications (1)

Publication Number Publication Date
DK2509619T3 true DK2509619T3 (da) 2021-03-08

Family

ID=44146200

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10836746.7T DK2509619T3 (da) 2009-12-11 2010-12-10 Behandlingsfremgangsmåder ved hjælp af stamcellemobilisatorer og immunsuppressive midler

Country Status (13)

Country Link
EP (2) EP2509619B1 (da)
CY (1) CY1124082T1 (da)
DK (1) DK2509619T3 (da)
ES (1) ES2855428T3 (da)
HR (1) HRP20210334T1 (da)
HU (1) HUE053293T2 (da)
LT (1) LT2509619T (da)
PL (1) PL2509619T3 (da)
PT (1) PT2509619T (da)
RS (1) RS61543B1 (da)
SI (1) SI2509619T1 (da)
SM (1) SMT202100127T1 (da)
WO (1) WO2011072216A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078746A2 (en) * 2010-12-07 2012-06-14 The Johns Hopkins University Compositions and methods for mobilizing stem cells
EP2946008A4 (en) * 2013-01-15 2016-07-20 Ohio State Innovation Foundation PROCESS FOR MOBILIZING HEMATOPOETIC STEM CELLS
EP3030232B1 (en) * 2013-04-29 2022-07-06 Medregen, LLC Wound healing via autologous stem cell mobilization
WO2021080331A1 (ko) * 2019-10-25 2021-04-29 사회복지법인 삼성생명공익재단 면역억제제를 포함하는 줄기세포의 치료효과 증진용 조성물 및 이를 이용한 줄기세포 치료효과 증진방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
JP2003523940A (ja) 1999-05-11 2003-08-12 オーソ−マクネイル ファーマシューティカル インコーポレイテッド エリスロポエチン投与の薬物速度論的および薬力学的モデリング
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
MXPA03002325A (es) 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
PL372705A1 (en) 2001-09-12 2005-07-25 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
WO2005039595A1 (ja) * 2003-10-23 2005-05-06 Chugai Pharmaceutical Co., Ltd. シクロホスファミドを有効成分とする末梢循環障害改善又は治療剤
JP5135795B2 (ja) * 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
WO2009074807A2 (en) * 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection

Also Published As

Publication number Publication date
HRP20210334T1 (hr) 2021-04-02
ES2855428T3 (es) 2021-09-23
LT2509619T (lt) 2021-04-12
WO2011072216A9 (en) 2011-10-13
EP2509619A2 (en) 2012-10-17
EP2509619B1 (en) 2020-12-09
EP3808368A3 (en) 2021-07-21
PL2509619T3 (pl) 2021-06-14
EP3808368A2 (en) 2021-04-21
CY1124082T1 (el) 2022-05-27
HUE053293T2 (hu) 2021-06-28
RS61543B1 (sr) 2021-04-29
EP2509619A4 (en) 2013-08-21
SMT202100127T1 (it) 2021-05-07
PT2509619T (pt) 2021-03-11
EP3808368B1 (en) 2026-03-04
WO2011072216A2 (en) 2011-06-16
SI2509619T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
EP2315829A4 (en) INDUCED PLURIPOTENTIAL STEM CELLS
IL254144A0 (en) Methods for reprogramming cells and uses thereof
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
EP2414510A4 (en) INDUCED PLURIPOTENTIAL STEM CELLS
DK3290061T3 (da) Fremgangsmåder og anordninger til cellulær transplantation
DK3702371T5 (da) Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
DK3266367T3 (da) Systemer og fremgangsmåder til billeddannelse ved anvendelse af absorption
SG10201402428WA (en) Method of efficiently establishing induced pluripotent stem cells
EP2370445A4 (en) STEM CELL CULTURES
DK3450545T5 (da) Pluripotente stamceller opnået ved ikke-viral omprogrammering
DK2446246T3 (da) Indretning og fremgangsmåde til udvælgelse af partikler
DK2282558T3 (da) Høreapparat og fremgangsmåde
FI20096288A0 (fi) Formulations and methods for culturing stem cells
DK3444613T3 (da) Fremgangsmåder til diagnosticering og behandling af autisme
DK2620493T3 (da) Mesenkymale stamceller til behandling af CNS-sygdomme
BRPI0915146A2 (pt) programação e reprodução de células
DK2440253T3 (da) Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
BR112012005117A2 (pt) método de tratamento de esofagite eosinofílica
DK2456379T3 (da) Forbedringer ved og i forhold til reduktion og fjernelse af partikler
EP2280908A4 (en) METHOD AND STRUCTURE FOR NONLINEAR OPTICS
EP2398431A4 (en) TISSUE IMPLANTS AND CORRESPONDING METHODS
DK3311823T3 (da) Fremgangsmåder og sammensætninger til brydning af biofilm ved hjælp af chitosan-derivatsammensætninger
DK2295235T3 (da) Fiberforstærket plaststruktur og fremgangsmåde til fremstilling af den fiberforstærkede plaststruktur
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK2231678T3 (da) Fremgangsmåde til selektiv deprotonisering og funktionalisering af 1-fluor-2-substituerede 3-chlorbenzener